Midiana

Drospirenone/Ethinylestradiol, the active ingredient in Midiana, is a combined oral contraceptive presented as a tablet for oral use. It prevents pregnancy in women of reproductive age by inhibiting ovulation and altering cervical mucus.

GNH USA supplies Midiana as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Midiana, a combined oral contraceptive, acts on the hypothalamic‑pituitary‑ovarian axis to prevent conception.

Prevention of pregnancy: provides reliable contraceptive protection for women of childbearing potential. Menstrual cycle regulation: helps establish a regular 28‑day cycle and reduces heavy menstrual bleeding. Acne management: may improve mild to moderate acne associated with hormonal fluctuations.

Common Side Effects: - Nausea or upset stomach - Breast tenderness or enlargement - Headache or migraine - Weight gain or fluid retention - Mood changes or irritability - Spotting or breakthrough bleeding

Serious or Rare Side Effects: - Deep vein thrombosis or pulmonary embolism - Stroke or transient ischemic attack - Myocardial infarction - Severe allergic reaction (anaphylaxis) - Liver dysfunction or jaundice - Vision changes or eye pain

Before prescribing Midiana, clinicians should consider several safety factors. - Contraindications: known thrombophilia, estrogen‑dependent tumor, active liver disease, or confirmed pregnancy. - Smoking: avoid use in women over 35 who smoke due to increased thrombotic risk. - Blood pressure: monitor patients with hypertension; uncontrolled high BP is a contraindication. - Drug interactions: review concomitant medications that may alter hormone levels. - Regular follow‑up: schedule periodic assessments to evaluate efficacy and tolerability. - Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Midiana may interact with several medicines that affect hormone metabolism.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine) can markedly reduce contraceptive effectiveness. - Protease inhibitors (e.g., ritonavir) may increase the risk of thrombotic events. - Concurrent use with other estrogen‑containing products (e.g., hormone replacement therapy) can raise estrogen exposure.

Moderate Interactions (Monitor Closely): - Antifungal agents such as ketoconazole may increase plasma concentrations of ethinylestradiol. - Selective serotonin reuptake inhibitors (SSRIs) can modestly increase bleeding risk. - Diuretics may affect fluid balance and blood pressure, requiring closer monitoring.